CAR T, bispecific antibodies, and oral CELMoDs—expand options, protect QOL, and raise hopes of cure, notes Asya Nina ...

The CAR-PRISM trial enrolled patients with high-risk smoldering multiple myeloma as defined by the 20/2/20 model: plasma ...

It’s a reasonable hope, given the results of that trial, which researchers presented at the American Association for Cancer ...

A single infusion of ciltacabtagene autoleucel (Carvykti) led to a 100% minimal residual disease (MRD)-negativity rate in ...

Results of the single-center, phase 2 CAR-PRISM (PRecision Intervention Smoldering Myeloma) clinical trial, the first to ...

Chemotherapy is a treatment that uses strong medicines to kill cancer cells or slow their growth. It is a type of systemic therapy, which means it travels through the bloodstream to reach and attack ...

Complete and durable regression and anti-tumor immune memory following treatment with FHD-909 (LY4050784) in combination with an anti-PD-1 ...

CAR T-cell therapy is a one-time intensive treatment that could potentially lead to a long remission, where Tec-Dara is an "off-the-shelf" option that you will need to stay on long-term.

Study finds how multiple myeloma cells adapt to immunotherapy, helping explain why patients relapse and guiding personalized ...

The second most common cancer in the hematologic (blood) cancer category is multiple myeloma. It accounts for about 13% of all cases of blood cancer. 63% of ...

OPN-6602 Currently Treating Patients in Phase 1 Clinical Trial SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--April 15, 2026-- Opna Bio, a clinical-s ...

Common manifestations and complications of multiple myeloma (MM) can include bone complications, hypercalcemia, renal insufficiency, infection, skeletal lesions and anemia. Other less common ...